It’s not as simple as that. In the PUL 2.0 test of Capricor’s HOPE-2 trial, CAP1002 showed a decline in strength for participants over 12 months, but 65% less decline than placebo.
At the 6 month point, the same length of ANP’s P2a trial, CAP1002 showed an average increase in strength compared to the strength of the same participants at the beginning of the trial.
For General Information, page-2447
-
- There are more pages in this discussion • 1,080 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
